Skip to Main Content
Yale School of Medicine
About YSM
Faculty
Staff
Students
Residents & Fellows
Patients
Researchers
Alumni
Yale School of Medicine
/
Rheumatology, Allergy & Immunology
MENU
Yale School of Medicine
MENU
Rheumatology, Allergy & Immunology
Rheumatology
Patient Care
Research
Clinical & Translational Research Lab (YR-CTRL)
Immune Profiling
Inflammation and Innate Immunity
In Vivo Imaging Facility
Lupus
Lyme Disease
Microbiome Research
Research Training Faculty
Yale Transketolase Deficiency Program
Clinical Trials
Publications
Yale Rheumatology Fellowship Training
Clinical Training
Research Training
Current Fellows and Graduate Information
Faculty
Philanthropy
Allergy & Immunology
Patient Care
Research
Publications
Education & Training
Clinical Training
Research Training
Seminars
Application
Current Fellows
Faculty
Contact Us
Faculty
Publications
News & Events
Newsletter
February 2025
YSM Home
INFORMATION FOR
About YSM
Faculty
Staff
Students
Residents & Fellows
Patients
Researchers
Alumni
Home
Rheumatology
Research
Clinical & Translational Research Lab (YR-CTRL)
Immune Profiling
Inflammation and Innate Immunity
In Vivo Imaging Facility
Lupus
Lyme Disease
Microbiome Research
Research Training Faculty
Yale Transketolase Deficiency Program
Clinical Trials
Publications
Clinical Trials
Brain and Nervous System
A Phase II, Multicenter, Prospective Study of Sacituzumab Govitecan in Recurrent Glioblastoma
Phase I
An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic ER+, HER2- Breast Cancer
Other Urinary, Urinary Bladder
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-103, a Nectin4/Trop2 ADC, as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Breast
A Phase II Trial to Improve Safety of Capivasertib for HR+/HER2- Metastatic Breast Cancer
Corpus Uteri
A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer
Show More
Back to Top
Your browser is antiquated and no longer supported on this website. Please update your browser or switch to Chrome, Firefox or Safari.
You can update your IE here:
https://support.microsoft.com/en-us/help/17621/internet-explorer-downloads
[8330,3053]
{"namedChunks":["modules-page-components-ComponentWrapper","features-clinical-trial-components-ClinicalTrialListing","modules-footer-components-Footer"]}